Michael Burkes Brophy Sells 1,523 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,523 shares of Natera stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $139,171.74. Following the transaction, the chief financial officer now directly owns 73,039 shares of the company’s stock, valued at $6,674,303.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The stock was sold at an average price of $65.09, for a total value of $210,566.15.

Natera Trading Up 0.5 %

NASDAQ:NTRA opened at $91.50 on Thursday. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The stock has a market capitalization of $11.05 billion, a PE ratio of -24.29 and a beta of 1.37. The business’s 50-day simple moving average is $86.85 and its 200-day simple moving average is $66.82.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Sell-side analysts expect that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently modified their holdings of the business. Simplicity Wealth LLC bought a new stake in Natera in the 1st quarter valued at approximately $223,000. Fifth Third Bancorp lifted its stake in Natera by 3.5% in the 1st quarter. Fifth Third Bancorp now owns 6,432 shares of the medical research company’s stock valued at $588,000 after acquiring an additional 216 shares in the last quarter. Arcadia Investment Management Corp MI lifted its stake in Natera by 47.8% in the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 174 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in Natera in the 1st quarter valued at approximately $2,606,000. Finally, Maryland State Retirement & Pension System raised its stake in shares of Natera by 11.2% during the 1st quarter. Maryland State Retirement & Pension System now owns 8,535 shares of the medical research company’s stock worth $761,000 after purchasing an additional 857 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NTRA shares. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Tuesday. The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. BTIG Research lifted their price objective on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Finally, Canaccord Genuity Group boosted their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.